Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The rationale for long-term antidepressant therapy

S Kasper1

  • 1Psychiatric Department, University of Vienna, Austria.

International Clinical Psychopharmacology
|January 1, 1993
PubMed
Summary

Depressive disorders are often recurrent. Continuation therapy for 4-6 months is recommended after remission, with long-term maintenance pharmacotherapy for high-risk patients to manage severity and refractoriness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

ESMO gastrointestinal oncology·2026
Same author

Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers-OncoVR.

ESMO gastrointestinal oncology·2026
Same author

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

ESMO gastrointestinal oncology·2026
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

Human <i>in vivo</i> assessment of ketamine binding of the serotonin transporter-follow up at a higher dose.

Frontiers in neuroscience·2025
Same author

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

ESMO open·2025

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Depressive disorders are frequently recurrent, impacting quality of life and productivity.
  • Acute phase treatment aims for remission, but relapse is common.
  • Recurrence can lead to increased severity and treatment resistance.

Purpose of the Study:

  • To review the rationale for long-term treatment of depressive disorders.
  • To provide practical guidelines for maintenance pharmacotherapy.
  • To address the management of recurrent depressive episodes.

Main Methods:

  • Review of controlled clinical trial data.
  • Analysis of treatment guidelines for depressive disorders.
  • Synthesis of evidence supporting long-term pharmacotherapy.

Main Results:

  • Continuation therapy of 4-6 months is recommended post-remission.
  • Maintenance pharmacotherapy is crucial for patients at risk of recurrence.
  • Depression can become more severe and refractory with repeated episodes.

Conclusions:

  • Long-term treatment strategies are essential for managing recurrent depressive disorders.
  • Maintenance pharmacotherapy offers a viable approach for preventing relapse and managing refractory symptoms.
  • Evidence supports a phased approach to treatment, including continuation and maintenance therapy.

Related Experiment Videos